Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:PRTC NASDAQ:SNDL OTCMKTS:TBUFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.50+0.7%$1.39$1.01▼$3.45$424.94M1.051.59 million shs701,291 shsPRTCPureTech Health$19.06+3.0%$17.92$13.30▼$25.00$457.82M1.114,889 shs661 shsSNDLSNDL$1.54-1.3%$1.31$1.15▼$2.40$404.68M3.41.96 million shs2.28 million shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+3.47%-1.97%+9.16%+28.45%-53.29%PRTCPureTech Health-0.70%+3.69%-0.36%+9.00%-17.98%SNDLSNDL+4.70%+9.86%+21.88%+11.43%-28.44%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca2.621 of 5 stars3.52.00.00.02.22.50.6PRTCPureTech Health2.518 of 5 stars3.85.00.00.01.90.00.0SNDLSNDL1.4171 of 5 stars2.03.00.00.01.40.01.3TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57207.84% UpsidePRTCPureTech Health 3.50Strong Buy$45.00136.16% UpsideSNDLSNDL 0.00N/A$4.00160.59% UpsideTBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TBUFF, PRTC, SNDL, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/APRTCPureTech Health$4.32M106.09$2.44 per share7.80$17.04 per share1.12SNDLSNDL$671.81M0.60N/AN/A$3.15 per share0.49TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)SNDLSNDL-$69.18M-$0.29N/AN/AN/A-11.48%-9.02%-7.60%7/31/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TBUFF, PRTC, SNDL, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ERASErasca-$0.12N/AN/AN/AN/AN/A7/31/2025Q2 2025SNDLSNDL-$0.04N/AN/AN/A$231.50 millionN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35PRTCPureTech HealthN/A9.339.33SNDLSNDL0.104.623.12TBUFFTribute Pharmaceuticals CanadaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%PRTCPureTech Health0.04%SNDLSNDLN/ATBUFFTribute Pharmaceuticals CanadaN/AInsider OwnershipCompanyInsider OwnershipERASErasca14.40%PRTCPureTech Health5.30%SNDLSNDLN/ATBUFFTribute Pharmaceuticals CanadaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionablePRTCPureTech Health10024.03 million22.75 millionNot OptionableSNDLSNDL2,516262.78 millionN/AOptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableTBUFF, PRTC, SNDL, and ERAS HeadlinesRecent News About These CompaniesSimone Biles pays tribute to husband Jonathan Owens with tiny new tattooSeptember 21, 2024 | pagesix.comPKid Rock's Toby Keith Tribute Concert Broke Taylor Swift's Audience Record?September 14, 2024 | snopes.comSTRANSFORMERS ONE - Advance Screening & Prize Pack ContestSeptember 12, 2024 | tribute.caTCate Blanchett Calls For Sustainability In Film Industry At TIFF Tribute Awards: “There Is A Moral Imperative To Make This Switch”September 11, 2024 | deadline.comDInside the TIFF Tribute Awards: Angelina Jolie Asks for No Photographs and Viggo Mortensen Decries David Cronenberg’s Oscar SnubsSeptember 11, 2024 | variety.comVTIFF 2024: Tragically Hip series honors beloved Canadian bandSeptember 6, 2024 | reuters.comTop country stars honor Toby Keith in a new special. Here's how to watchSeptember 1, 2024 | today.comT‘Survivor’s Remorse’ actress Erica Ash dead at 46: Loni Love, Bow Wow and more pay tributeJuly 31, 2024 | pagesix.comPValeo Pharma Inc. (VPHIF)May 17, 2024 | finance.yahoo.comAbout Tribute.caApril 1, 2024 | tribute.caTMacGregor: A Remembrance Day tribute to Canada's Korean War veteransNovember 13, 2023 | ottawacitizen.comOChurch Under Fire: Canada's War on Christianity - CastOctober 25, 2023 | tribute.caTTerry Funk dies, aged 79: Pro wrestling industry pays tribute to hardcore iconAugust 27, 2023 | sportingnews.comSRon Canada Biography & MoviesJuly 23, 2023 | tribute.caTWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.May 2, 2023 | yahoo.comAlberta tattoo artists pay tribute to laser removal expert who helped people move past traumaApril 29, 2023 | cbc.caMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONApril 27, 2023 | finance.yahoo.comHumboldt holds tribute five years after deadly bus crashApril 8, 2023 | thestar.comTPaul O’Grady fans break down in tears over Lily Savage’s Blankety Blank tribute episode after shock deathApril 3, 2023 | thesun.co.ukGamer Crochets Destiny 2 Tribute to Zavalla Actor Lance ReddickApril 3, 2023 | gamerant.comGNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBUFF, PRTC, SNDL, and ERAS Company DescriptionsErasca NASDAQ:ERAS$1.50 +0.01 (+0.67%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.00 (+0.27%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.PureTech Health NASDAQ:PRTC$19.06 +0.56 (+3.01%) Closing price 03:58 PM EasternExtended Trading$19.06 0.00 (-0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.SNDL NASDAQ:SNDL$1.54 -0.02 (-1.28%) Closing price 04:00 PM EasternExtended Trading$1.54 -0.01 (-0.32%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
